(placeholder)

中文

Crystal Pharmatech, Co is honored to announce it has expanded its’ leadership team to include Dr. Kevin Wang. This reflects Crystal Pharmatech’s continued strategy to expand CMC services towards becoming a better partner for our clients.

As Vice President, Head of Chemistry, Dr. Wang will report directly to the CSO, Yanfeng Zhang, and work closely with the Business Development team to ensure clients are offered the highest level of service in the industry.


Before joining Crystal Pharmatech, Dr. Wang worked for 13 years in research and management roles for the pharmaceutical industry.  In 2009, he started ACS Scientific Inc. which is focused on custom synthesis, scale up and process research. Before founding ACS Scientifc, he worked on a novel HCV drug as a process chemist at PTC Therapeutics. His expertise spans from drug discovery to process chemistry.


“Kevin will bring extensive organic synthesis experience to Crystal Pharmatech which will allow us to continue adding value to partnerships with our clients” explains Dr. Alex M. Chen, CEO of Crystal Pharmatech Co., Ltd.  “Our clients are asking for a truly integrated CMC platform that combines Crystal Pharmatech qualities including speed and project management.  Hiring Kevin ensures we continue to be the leading technology-driven CRO focused on CMC services.”  


Crystal Pharmatech is a globaltechnology-driven research organization with labs in China and the US with combined over 54,000 sq. ft. and over 100 employees.  Our research focuses on form screening/selection, crystallization development and add-on CMC services that guide pharmaceutical companies to develop new drugs efficiently and effectively. With a leading platform in solid form research, Crystal Pharmatech has built successful business relationships with over 300 pharmaceutical companies with a primary focus of progressing compounds from candidate selection to IND application.

Crystal Pharmatech, Co is honored to announce it has expanded its’ leadership team to include Dr. Kevin Wang.

This reflects Crystal Pharmatech’s continued strategy to expand CMC services towards becoming a better partner for our clients.